BMT CTN Protocol 1304 / DFCI 10-106

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.

Below are protocol-related documents, which may be periodically updated.

            Protocol Chair: Paul Richardson

            Protocol Coordinator: Amy Foley (BMT CTN)


 The BMT CTN is providing accrual credit for patients enrolled on this study as of November 16, 2013.  The BMT CTN is only providing accrual credit; Dana-Farber is managing the study and handles the activation process and study management activities.